AU2003240705A1 - Morpholinylmethylureas ccr-3 receptor antagonists - Google Patents

Morpholinylmethylureas ccr-3 receptor antagonists

Info

Publication number: AU2003240705A1
Authority: AU; Australia
Prior art keywords: morpholinylmethylureas; ccr; receptor antagonists; antagonists; receptor
Prior art date: 2002-05-22
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

AU2003240705A

Inventor

Michael Dennis Dowle

Paul Martin Gore

Simon Teanby Hodgson

Martin Redpath Johnson

Duncan Bruce Judd

Tracy Jane Redfern

John Edward Robinson

Stephen Swanson

Naimisha Trivedi

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Glaxo Group Ltd

Original Assignee

Glaxo Group Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-05-22

Filing date

2003-05-20

Publication date

2003-12-02

2003-05-20 Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd

2003-12-02 Publication of AU2003240705A1 publication Critical patent/AU2003240705A1/en

Status Abandoned legal-status Critical Current

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
- C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D267/02—Seven-membered rings
- C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D267/10—Seven-membered rings having the hetero atoms in positions 1 and 4 not condensed with other rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
- C07D279/12—1,4-Thiazines; Hydrogenated 1,4-thiazines not condensed with other rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Pulmonology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

AU2003240705A 2002-05-22 2003-05-20 Morpholinylmethylureas ccr-3 receptor antagonists Abandoned AU2003240705A1 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GBGB0211759.6A GB0211759D0 (en)	2002-05-22	2002-05-22	Novel compounds
GB0211759.6		2002-05-22
PCT/EP2003/005446 WO2003097618A1 (en)	2002-05-22	2003-05-20	Morpholinylmethylureas ccr-3 receptor antagonists

Publications (1)

Publication Number	Publication Date
AU2003240705A1 true AU2003240705A1 (en)	2003-12-02

Family

ID=9937176

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AU2003240705A Abandoned AU2003240705A1 (en)	2002-05-22	2003-05-20	Morpholinylmethylureas ccr-3 receptor antagonists

Country Status (3)

Country	Link
AU (1)	AU2003240705A1 (en)
GB (1)	GB0211759D0 (en)
WO (1)	WO2003097618A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1608319A4 (en)	2003-04-03	2007-02-28	Univ California	IMPROVED INHIBITORS FOR SOLUBLE EPOXY HYDROLASE
CA2559665A1 (en)	2004-03-16	2005-09-29	The Regents Of The University Of California	Reducing nephropathy with inhibitors of soluble epoxide hydrolase and epoxyeicosanoids
ZA200703613B (en)	2004-10-20	2009-05-27	Univ California	Improved inhibitors for the soluble epoxide hydrolase
TW200808723A (en)	2006-03-13	2008-02-16	Univ California	Conformationally restricted urea inhibitors of soluble epoxide hydrolase
TWI452044B (en) *	2007-06-15	2014-09-11	Mitsubishi Tanabe Pharma Corp	Morpholine derivative
US9296693B2 (en)	2010-01-29	2016-03-29	The Regents Of The University Of California	Acyl piperidine inhibitors of soluble epoxide hydrolase
KR20180052762A (en)	2015-09-22	2018-05-18	글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드	Pyridinone dicarboxamide for use as a bromo domain inhibitor
AU2017245641A1 (en)	2016-04-07	2018-09-13	Glaxosmithkline Intellectual Property (No.2) Limited	Pyridyl derivatives as bromodomain inhibitors
CN109705052B (en) *	2019-01-25	2020-12-08	苏州大学	A kind of method for preparing 1,4-dihydrooxazine
AU2021325024A1 (en) *	2020-08-11	2023-04-13	Board Of Trustees Of Michigan State University	Proteasome enhancers and uses thereof
CN114436983B (en) *	2021-11-23	2023-05-23	辽宁中医药大学	Oleraze and Oleraoxazine acid in purslane and their extraction and separation methods

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1995031431A1 (en) *	1994-05-18	1995-11-23	Nisshin Flour Milling Co., Ltd.	Novel diaminomethylidene derivative
CA2372887A1 (en) *	1999-05-25	2000-11-30	Sepracor Inc.	Heterocyclic analgesic compounds and their use
CA2423251A1 (en) *	2000-09-29	2002-04-04	Glaxo Group Limited	Morpholin-acetamide derivatives for the treatment of inflammatory diseases
NZ525055A (en) *	2000-09-29	2004-09-24	Glaxo Group Ltd	Compounds useful in the treatment of inflammatory diseases

2002
- 2002-05-22 GB GBGB0211759.6A patent/GB0211759D0/en not_active Ceased
2003
- 2003-05-20 AU AU2003240705A patent/AU2003240705A1/en not_active Abandoned
- 2003-05-20 WO PCT/EP2003/005446 patent/WO2003097618A1/en not_active Ceased

Also Published As

Publication number	Publication date
WO2003097618A1 (en)	2003-11-27
GB0211759D0 (en)	2002-07-03

Publication	Publication Date	Title
AU2003231513A1 (en)	2003-12-02	Pgd2 receptor antagonist
AU2003261392A1 (en)	2004-02-23	M3muscarinic acetylcholine receptor antagonists
AU2003241836A1 (en)	2004-04-23	Lpa receptor antagonists
IL165841A0 (en)	2006-01-15	Mchir antagonists
AUPR833401A0 (en)	2001-11-08	G protein-coupled receptor antagonists
AU2002367424A1 (en)	2003-07-24	Androgen receptor antagonists
AU2003299807A1 (en)	2004-07-22	Heteroarylalkanoic acids as integrin receptor antagonists
AU2003255501A1 (en)	2004-04-30	Cxcr4 receptor antagonists
PL378753A1 (en)	2006-05-15	Ccr-3 receptor antagonists
AU2003291959A1 (en)	2004-07-14	Novel glucagon antagonists
IL164016A0 (en)	2005-12-18	Azetidine derivatives as ccr-3 receptor antagonists
IL165727A0 (en)	2006-01-15	Chemokine antagonists
AU2003267088A1 (en)	2004-04-30	Chemokine receptor antagonists as therapeutic agents
AU2003260072A1 (en)	2004-03-19	Antagonists of chemokine receptors
AU2003236247A1 (en)	2003-11-17	Bombesin antagonists
AU2003240705A1 (en)	2003-12-02	Morpholinylmethylureas ccr-3 receptor antagonists
AU2003248356A1 (en)	2003-09-09	Beta3-adrenergic receptor agonists
GB0203412D0 (en)	2002-04-03	5-HT 2B receptor antagonists
AU2003287219A1 (en)	2004-05-25	Il-8 receptor antagonists
GB0226227D0 (en)	2002-12-18	Receptors
PL370367A1 (en)	2005-05-16	Ccr-3 receptor antagonists v
PL373275A1 (en)	2005-08-22	Ccr-3 receptor antagonists vii
AU2003240730A1 (en)	2003-12-12	Morpholinylmethylureas ccr-3 receptor antagonist
GB0215389D0 (en)	2002-08-14	Receptor
AU2003242244A1 (en)	2003-12-22	Chemokine receptor antagonist

Legal Events

Date	Code	Title	Description
2005-02-10	MK6	Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase